GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 04 Aug, 1:26AM

113.18

0.89 (0.79%)

Add to watchlist

Previous Close	112.29
Open	112.26
Volume	5,016,408
Avg. Volume (3M)	7,757,511
Market Cap	140,787,990,528

Price / Earnings (TTM)	23.78
Price / Earnings (Forward)	12.76
Price / Sales	4.83
Price / Book	6.97

52 Weeks Range	72.43 (-36%) — 119.96 (5%)
Earnings Date	7 Aug 2025
TTM Dividend Yield	2.08%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Bearish
	Drug Manufacturers - General (Global)	Bullish	Bearish
Stock	Gilead Sciences, Inc.	Bullish	Bullish

AIStockmoo Score

1.7

Analyst Consensus	1.5
Insider Activity	-1.5
Price Volatility	2.0
Technical Moving Averages	2.5
Technical Oscillators	4.0
Average	1.70

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
GILD	141 B	2.08%	23.78	6.97
AMGN	161 B	3.14%	24.45	21.55
AZN	263 B	1.85%	31.96	5.80
SNY	120 B	4.60%	16.03	1.49
GRFS	6 B	1.73%	28.00	1.12
BIIB	21 B	-	13.64	1.29

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.10%
% Held by Institutions	89.79%

52 Weeks Range	72.43 (-36%) — 119.96 (5%)
Price Target Range	98.00 (-13%) — 145.00 (28%)
High	145.00 (JP Morgan, 28.12%)	Buy
Median	127.00 (12.21%)
Low	98.00 (RBC Capital, -13.41%)	Hold
Average	125.00 (10.44%)
Total	5 Buy, 2 Hold
Avg. Price @ Call	118.05

Firm	Date	Target Price	Call	Price @ Call
TD Cowen	23 Oct 2025	125.00 (10.44%)	Buy	122.81
Citigroup	08 Oct 2025	135.00 (19.28%)	Buy	118.25
JP Morgan	16 Sep 2025	145.00 (28.11%)	Buy	110.86
RBC Capital	08 Aug 2025	98.00 (-13.41%)	Hold	119.41
Truist Securities	08 Aug 2025	127.00 (12.21%)	Buy	119.41
UBS	08 Aug 2025	112.00 (-1.04%)	Hold	119.41
Needham	25 Jul 2025	133.00 (17.51%)	Buy	116.20

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
DICKINSON ANDREW D	-	118.30	-2,500	-295,750
MERCIER JOHANNA	-	118.30	-3,000	-354,900
Aggregate Net Quantity				-5,500
Aggregate Net Value ($)				-650,650
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				118.30

Name	Holder	Date	Type	Quantity	Price	Value ($)
MERCIER JOHANNA	Officer	15 Oct 2025	Automatic sell (-)	3,000	118.30	354,900
DICKINSON ANDREW D	Officer	15 Oct 2025	Automatic sell (-)	2,500	118.30	295,750

Date	Type	Details
19 Oct 2025	Announcement	Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
19 Oct 2025	Announcement	Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
15 Oct 2025	Announcement	Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
13 Oct 2025	Announcement	Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
09 Oct 2025	Announcement	Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
25 Sep 2025	Announcement	Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
04 Sep 2025	Announcement	Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
04 Sep 2025	Announcement	Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
03 Sep 2025	Announcement	Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
26 Aug 2025	Announcement	European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
21 Aug 2025	Announcement	Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
20 Aug 2025	Announcement	Gilead Sciences to Present at Upcoming Investor Conferences
07 Aug 2025	Announcement	Gilead Sciences Announces Second Quarter 2025 Financial Results
31 Jul 2025	CNBC	Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
25 Jul 2025	Announcement	Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
24 Jul 2025	Announcement	Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Show more

TTM Dividend Yield	2.08%
5Y Average Dividend Yield	3.80%
Payout Ratio	65.13%
Expected Next Dividend Payment	Dec 2025

Ex Date	Announcement Date	Payment Date	Details
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 Cash
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 Cash
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 Cash
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 Cash
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 Cash
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 Cash
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 Cash
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 Cash
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 Cash
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 Cash
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 Cash
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 Cash
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 Cash
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 Cash
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 Cash
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 Cash
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 Cash
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 Cash
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 Cash
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 Cash
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 Cash
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 Cash
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 Cash
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 Cash
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 Cash
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 Cash
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 Cash
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 Cash
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 Cash
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 Cash
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 Cash
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 Cash
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 Cash
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 Cash
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 Cash
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 Cash
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 Cash
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 Cash
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 Cash
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 Cash
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	1.58	2	1.40
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	20.76%
Operating Margin (TTM)	38.49%
Diluted EPS (TTM)	4.76
Quarterly Revenue Growth (YOY)	-0.30%
Quarterly Earnings Growth (YOY)	24.80%

Total Debt/Equity (MRQ)	130.79%
Current Ratio (MRQ)	1.37
Operating Cash Flow (TTM)	10.37 B
Levered Free Cash Flow (TTM)	9.99 B

Return on Assets (TTM)	12.14%
Return on Equity (TTM)	32.65%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)